Literature DB >> 32412785

Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow.

Matthew Perry Koppinger1, Marissa Anne Lopez-Pier2,3, Rinku Skaria4, Preston Royal Harris1, John P Konhilas1,2,3,4.   

Abstract

Disruption of the normal gut microbiome (dysbiosis) is implicated in the progression and severity of myriad disorders, including hypercholesterolemia and cardiovascular disease. Probiotics attenuate and reverse gut dysbiosis to improve cardiovascular risk factors like hypertension and hypercholesterolemia. Lactobacillus reuteri is a well-studied lactic acid-producing probiotic with known cholesterol-lowering properties and anti-inflammatory effects. In the present study, we hypothesized that L. reuteri delivered to hypercholesterolemic low-density lipoprotein receptor knockout (LDLr KO) mice will reduce cholesterol levels and minimize cardiac injury from an ischemic insult. L. reuteri [1 × 109 or 50 × 106 colony-forming units (CFU)/day] was administered by oral gavage to wild-type mice and LDLr KO for up to 6 wk followed by an ischemia-reperfusion (I/R) protocol. After 4 wk of gavage, total serum cholesterol in wild-type mice receiving saline was 113.5 ± 5.6 mg/dL compared with 113.3 ± 6.8 and 101.9 ± 7.5 mg/dL in mice receiving 1 × 109 or 50 × 106 CFU/day, respectively. Over the same time frame, administration of L. reuteri at 1 × 109 or 50 × 106 CFU/day did not lower total serum cholesterol (283.0 ± 11.1, 263.3 ± 5.0, and 253.1 ± 7.0 mg/dL; saline, 1 × 109 or 50 × 106 CFU/day, respectively) in LDLr KO mice. Despite no impact on total serum cholesterol, L. reuteri administration significantly attenuated cardiac injury following I/R, as evidenced by smaller infarct sizes compared with controls in both wild-type and LDLr KO groups. In conclusion, daily L. reuteri significantly protected against cardiac injury without lowering cholesterol levels, suggesting anti-inflammatory properties of L. reuteri uncoupled from improvements in serum cholesterol.NEW & NOTEWORTHY We demonstrated that daily delivery of Lactobacillus reuteri to wild-type and hypercholesterolemic lipoprotein receptor knockout mice attenuated cardiac injury following ischemia-reperfusion without lowering total serum cholesterol in the short term. In addition, we validated protection against cardiac injury using histology and immunohistochemistry techniques. L. reuteri offers promise as a probiotic to mitigate ischemic cardiac injury.

Entities:  

Keywords:  cholesterol; gut microbiota, Lactobacillus reuteri; myocardial infarction; probiotics

Mesh:

Substances:

Year:  2020        PMID: 32412785      PMCID: PMC7474440          DOI: 10.1152/ajpheart.00569.2019

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  50 in total

Review 1.  Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism.

Authors:  Jeremy K Nicholson; Ian D Wilson
Journal:  Nat Rev Drug Discov       Date:  2003-08       Impact factor: 84.694

Review 2.  Host-gut microbiota metabolic interactions.

Authors:  Jeremy K Nicholson; Elaine Holmes; James Kinross; Remy Burcelin; Glenn Gibson; Wei Jia; Sven Pettersson
Journal:  Science       Date:  2012-06-06       Impact factor: 47.728

3.  Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse.

Authors:  C A Danilo; E Constantopoulos; L A McKee; H Chen; J A Regan; Y Lipovka; S Lahtinen; L K Stenman; T-V V Nguyen; K P Doyle; M J Slepian; Z I Khalpey; J P Konhilas
Journal:  Benef Microbes       Date:  2017-04-14       Impact factor: 4.205

4.  A human gut microbial gene catalogue established by metagenomic sequencing.

Authors:  Junjie Qin; Ruiqiang Li; Jeroen Raes; Manimozhiyan Arumugam; Kristoffer Solvsten Burgdorf; Chaysavanh Manichanh; Trine Nielsen; Nicolas Pons; Florence Levenez; Takuji Yamada; Daniel R Mende; Junhua Li; Junming Xu; Shaochuan Li; Dongfang Li; Jianjun Cao; Bo Wang; Huiqing Liang; Huisong Zheng; Yinlong Xie; Julien Tap; Patricia Lepage; Marcelo Bertalan; Jean-Michel Batto; Torben Hansen; Denis Le Paslier; Allan Linneberg; H Bjørn Nielsen; Eric Pelletier; Pierre Renault; Thomas Sicheritz-Ponten; Keith Turner; Hongmei Zhu; Chang Yu; Shengting Li; Min Jian; Yan Zhou; Yingrui Li; Xiuqing Zhang; Songgang Li; Nan Qin; Huanming Yang; Jian Wang; Søren Brunak; Joel Doré; Francisco Guarner; Karsten Kristiansen; Oluf Pedersen; Julian Parkhill; Jean Weissenbach; Peer Bork; S Dusko Ehrlich; Jun Wang
Journal:  Nature       Date:  2010-03-04       Impact factor: 49.962

5.  n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.

Authors:  M G Riggs; R G Whittaker; J R Neumann; V M Ingram
Journal:  Nature       Date:  1977-08-04       Impact factor: 49.962

6.  Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial.

Authors:  M L Jones; C J Martoni; S Prakash
Journal:  Eur J Clin Nutr       Date:  2012-09-19       Impact factor: 4.016

7.  High-fat Diet-induced Intestinal Hyperpermeability is Associated with Increased Bile Acids in the Large Intestine of Mice.

Authors:  Yuki Murakami; Soichi Tanabe; Takuya Suzuki
Journal:  J Food Sci       Date:  2015-11-23       Impact factor: 3.167

8.  Evidence for hypocholesterolemic effect of Lactobacillus reuteri in hypercholesterolemic mice.

Authors:  M P Taranto; M Medici; G Perdigon; A P Ruiz Holgado; G F Valdez
Journal:  J Dairy Sci       Date:  1998-09       Impact factor: 4.034

9.  Hypolipidemic effects and safety of Lactobacillus reuteri 263 in a hamster model of hyperlipidemia.

Authors:  Wen-Ching Huang; Yi-Ming Chen; Nai-Wen Kan; Chun-Sheng Ho; Li Wei; Ching-Hung Chan; Hui-Yu Huang; Chi-Chang Huang
Journal:  Nutrients       Date:  2015-05-15       Impact factor: 5.717

Review 10.  PCSK9 inhibitors: A new era of lipid lowering therapy.

Authors:  Rahul Chaudhary; Jalaj Garg; Neeraj Shah; Andrew Sumner
Journal:  World J Cardiol       Date:  2017-02-26
View more
  3 in total

Review 1.  Guidelines for in vivo mouse models of myocardial infarction.

Authors:  Merry L Lindsey; Keith R Brunt; Jonathan A Kirk; Petra Kleinbongard; John W Calvert; Lisandra E de Castro Brás; Kristine Y DeLeon-Pennell; Dominic P Del Re; Nikolaos G Frangogiannis; Stefan Frantz; Richard J Gumina; Ganesh V Halade; Steven P Jones; Rebecca H Ritchie; Francis G Spinale; Edward B Thorp; Crystal M Ripplinger; Zamaneh Kassiri
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-08       Impact factor: 5.125

2.  Heart Failure Severity Closely Correlates with Intestinal Dysbiosis and Subsequent Metabolomic Alterations.

Authors:  Martina E Spehlmann; Ashraf Y Rangrez; Dhiraj P Dhotre; Nesrin Schmiedel; Nikita Chavan; Corinna Bang; Oliver J Müller; Yogesh S Shouche; Andre Franke; Derk Frank; Norbert Frey
Journal:  Biomedicines       Date:  2022-03-30

3.  Lactobacillus levels and prognosis of patients with acute myocardial infarction.

Authors:  Jing-Jing Cai; Yin Liu; Jie Wang; Jing-Xian Wang; Yuan Wang; Shi-Bo Xu; Zhuang Cui; Jing Gao
Journal:  J Geriatr Cardiol       Date:  2022-02-28       Impact factor: 3.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.